KalVista Pharmaceuticals, Inc.
KALV
$13.05
-$0.26-1.95%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.66% | -14.77% | -4.51% | 9.42% | -53.81% |
| Total Depreciation and Amortization | 13.97% | 0.88% | 1.34% | 2.28% | 5.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.38% | 357.89% | -5.37% | -81.84% | 457.19% |
| Change in Net Operating Assets | 106.31% | 2,525.82% | 109.22% | -113.91% | 1,709.50% |
| Cash from Operations | -23.51% | 17.56% | 1.44% | -166.27% | 45.21% |
| Capital Expenditure | -1,070.83% | 77.78% | -414.29% | -40.00% | 21.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -135.67% | -82.49% | 31.19% | 129.47% | -1,787.94% |
| Cash from Investing | -139.07% | -82.50% | 30.98% | 129.45% | -1,782.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.73% | 19,067.12% | -90.17% | -96.91% | 34,046.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -97.05% | -- | -- | -- | -- |
| Cash from Financing | -96.93% | 51,348.47% | -90.17% | -98.00% | 52,751.41% |
| Foreign Exchange rate Adjustments | 369.34% | -406.88% | 247.86% | 258.11% | 88.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.23% | 1,198.26% | 16,396.61% | -99.32% | 125.23% |